How Evaluate Supports Your Success
Forecasting, portfolio prioritisation and asset valuation decisions require increasingly detailed and reliable epidemiology data. However, drawing confident conclusions about the spread and burden of disease is difficult to achieve. It’s time consuming to gather all the necessary data; and experts are required to evaluate, standardise and consolidate multiple epidemiological data sources into a single body of evidence. Evaluate Epi enables to you:
Pinpoint market opportunities
Profile diseases in detail. Customise your view with insights on biomarkers, co-morbidities, line of therapy, disability scales, and age coverage from 0 to 100 in 5-year increments.
Optimise clinical trial design and planning
Quantify patient populations for clinical trial design selecting disease and conditions across 55 countries.
Forecast patient needs and sales trends
Conduct budget impact analysis, health economics modelling, and forecast future shifts in patient populations and their effect on sales.